BEIJING, Jan. 5, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that the Compensation Committee has approved to grant, and the Company has granted to Mr. Xing Jin, the chairman of the board of directors and the chief executive officer of the Company, 2,923,077 restricted share units of the Company (the "Restricted Share Units"), each representing the right to receive one Class A ordinary share of the Company upon vesting. The restricted share units were granted to Mr. Jin to recognize and reward his contribution to the Company and to incentivize him to lead the Company to greater business results as the Company explores new business initiatives.
To better align the Company's long-term strategies and the shareholders' interests, Mr. Jin has agreed not to sell more than one-third of the total Class A ordinary shares to be issued upon the vesting of the Restricted Share Units in each year ending December 31, 2024, 2025 and 2026.
About So-Young
So-Young is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young's strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.
For more information, please contact:
So-Young
Investor Relations
Ms. Vivian Xu
Phone: +86-10-8790-2012
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Christensen
In China
Mr. Christian Arnell
Phone: +852-2232-3968
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.31 |
Daily Change: | 0.02 1.50 |
Daily Volume: | 30,155 |
Market Cap: | US$133.570M |
December 01, 2023 November 20, 2023 November 13, 2023 October 12, 2023 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB